Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Anti-invasion Effects of Cannabinoids Agonist and Antagonist on Human Breast Cancer Stem Cells.

Mohammadpour F, Ostad SN, Aliebrahimi S, Daman Z.

Iran J Pharm Res. 2017 Fall;16(4):1479-1486.


Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.

Ladin DA, Soliman E, Griffin L, Van Dross R.

Front Pharmacol. 2016 Oct 7;7:361. eCollection 2016. Review.


Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.

Roche M, Finn DP.

Pharmaceuticals (Basel). 2010 Aug 10;3(8):2517-2553. Review.


The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.

Morell C, Bort A, Vara D, Ramos-Torres A, Rodríguez-Henche N, Díaz-Laviada I.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):248-57. doi: 10.1038/pcan.2016.19. Epub 2016 Jun 21.


Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.

Freund P, Porpaczy EA, Le T, Gruber M, Pausz C, Staber P, Jäger U, Vanura K.

PLoS One. 2016 Jun 1;11(6):e0156693. doi: 10.1371/journal.pone.0156693. eCollection 2016.


The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory.

Khan MI, Sobocińska AA, Czarnecka AM, Król M, Botta B, Szczylik C.

Curr Pharm Des. 2016;22(12):1756-66. Review.


Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis.

Sophocleous A, Marino S, Logan JG, Mollat P, Ralston SH, Idris AI.

J Biol Chem. 2015 Sep 4;290(36):22049-60. doi: 10.1074/jbc.M115.649608. Epub 2015 Jul 20.


Elucidating cannabinoid biology in zebrafish (Danio rerio).

Krug RG 2nd, Clark KJ.

Gene. 2015 Oct 10;570(2):168-79. doi: 10.1016/j.gene.2015.07.036. Epub 2015 Jul 17. Review.


Proapoptotic effect of endocannabinoids in prostate cancer cells.

Orellana-Serradell O, Poblete CE, Sanchez C, Castellón EA, Gallegos I, Huidobro C, Llanos MN, Contreras HR.

Oncol Rep. 2015 Apr;33(4):1599-608. doi: 10.3892/or.2015.3746. Epub 2015 Jan 21.


Cannabinoids as therapeutic agents in cancer: current status and future implications.

Chakravarti B, Ravi J, Ganju RK.

Oncotarget. 2014 Aug 15;5(15):5852-72. Review.


Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.

Cipriano M, Häggström J, Hammarsten P, Fowler CJ.

PLoS One. 2013 Jun 5;8(6):e65798. doi: 10.1371/journal.pone.0065798. Print 2013.


Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway.

Liu YJ, Fan HB, Jin Y, Ren CG, Jia XE, Wang L, Chen Y, Dong M, Zhu KY, Dong ZW, Ye BX, Zhong Z, Deng M, Liu TX, Ren R.

J Biol Chem. 2013 May 10;288(19):13551-62. doi: 10.1074/jbc.M113.453811. Epub 2013 Mar 28.


Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth.

Van Dross R, Soliman E, Jha S, Johnson T, Mukhopadhyay S.

Life Sci. 2013 Mar 19;92(8-9):463-6. doi: 10.1016/j.lfs.2012.09.025. Epub 2012 Oct 12. Review.


Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V.

Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x.


Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Seely KA, Lapoint J, Moran JH, Fattore L.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):234-43. doi: 10.1016/j.pnpbp.2012.04.017. Epub 2012 Apr 26. Review.


Cannabinoids, endocannabinoids, and cancer.

Hermanson DJ, Marnett LJ.

Cancer Metastasis Rev. 2011 Dec;30(3-4):599-612. doi: 10.1007/s10555-011-9318-8. Review.


Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.

Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I.

Cell Death Differ. 2011 Jul;18(7):1099-111. doi: 10.1038/cdd.2011.32. Epub 2011 Apr 8. Erratum in: Cell Death Differ. 2011 Jul;18(7):1237.


The endocannabinoid system and cancer: therapeutic implication.

Guindon J, Hohmann AG.

Br J Pharmacol. 2011 Aug;163(7):1447-63. doi: 10.1111/j.1476-5381.2011.01327.x. Review.


Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4.

Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, Egevad L, Granfors T, Fowler CJ.

PLoS One. 2010 Aug 19;5(8):e12275. doi: 10.1371/journal.pone.0012275.

Supplemental Content

Support Center